Introduction
Patients undergoing isolated coronary artery bypass grafting (CABG) are often at risk of severe bleeding because of recent exposure to potent antithrombotics. 1 Excessive bleeding and exposure to blood products are known to vary significantly between institutions, likely because of different patient-blood management strategies. [2] [3] [4] [5] However, there are no data on the possible impact of the individual patient risk of bleeding, late discontinuation of potent antiplatelets, and differences in the rate and nature of excessive bleeding requiring reoperation as the main determinants of such inter-institutional differences. We sought to investigate any inter-institutional variation in the adherence to early discontinuation of antithrombotics, perioperative bleeding, and use of blood products from the prospective, multicentre European Coronary Artery Bypass Grafting (E-CABG) registry.
Methods
The E-CABG registry is a prospective, multicentre observational study that enrolled patients undergoing isolated CABG at 16 European centres of cardiac surgery from Finland, France, Italy, Germany, Sweden, and UK. The detailed protocol and definition criteria have been published earlier. 6 Out of 7352 patients enrolled in the E-CABG registry, 181 were operated after the recruitment period. Further 53 patients were excluded because they were recruited from one centre only at the end of the study period. Overall, 7118 patients operated in 15 centres from January 2015 to December 2016 had complete data on the covariates and outcomes of interest and were included in the present analysis. Data were collected prospectively and underwent robust validation and checking of its quality.
Only data on timing of resternotomy and sources of bleeding were retrieved retrospectively. The study was approved by the Regional or Institutional Review Board of the participating centres. Informed consent was obtained when required by the Review Board, otherwise it was waived. The study is registered with the Clinical Trials Identifier NCT02319083 and was not supported financially. The participating centres did not adopt a common strategy of patient-blood management, and the indication for blood transfusion varied between centres. Point-ofcare testing of coagulation was performed in all centres only in case of excessive intra-or post-operative bleeding.
The risk of post-operative bleeding was estimated by the WILL-BLEED, 8 CRUSADE, 9 Papworth, 10 TRUST, 11 TRACK, 12 and CathPCI bleeding risk scores. 13 
Outcomes
The main outcome measures were reoperation for bleeding, severemassive bleeding defined as the Universal Definition of Perioperative Bleeding (UDPB) Classes 3-4, 7 and E-CABG bleeding Classes 2-3. 6 Secondary outcomes were chest drain output at 12 h after surgery, nadir haematocrit, red blood cell (RBC) transfusions, plasma transfusion, platelets transfusion, use of procoagulants, hospital/30-day death, length of stay in the intensive care unit, stroke, prolonged inotropic support, deep sternal wound infection/mediastinitis, acute kidney injury, renal replacement therapy, and post-operative atrial fibrillation. Reoperation for bleeding was defined as any resternotomy for excessive bleeding performed during the index hospitalization. According to the E-CABG bleeding classification, severe-massive bleeding was defined as any reoperation for excessive bleeding and/or transfusion >4 units of RBCs. 6 According to the UDPB bleeding classification, severe-massive bleeding was defined as chest tube blood loss within 12 h >1000 mL and/ or reoperation for excessive bleeding and/or transfusion >4 units of RBCs and/or transfusion >4 units of fresh frozen plasma after closure of the chest. 7 Use of procoagulants was defined as any administration of fibrinogen, prothrombin complex concentrate, cryoprecipitate, and recombinant factor VIIa intraoperatively during the index hospitalization. Nadir levels of haematocrit were defined as the lowest value measured on the day of surgery. Hospital/30-day mortality was defined as all-cause death occurring during the index hospitalization or within 30 days after CABG. Intensive care unit length of stay was defined as the number of days of treatment in the intensive care unit considering also any readmission during the same index hospitalization. Stroke was defined as any focal or global neurological syndrome occurring during the index hospitalization not resolving within 24 h. The diagnosis and nature of stroke was based on findings at computed tomography and/or magnetic resonance imaging of the brain and confirmed by a neurologist. Need of intra-aortic balloon pump and/or extracorporeal membrane oxygenation refers to the use of these mechanical circulatory supports method any time after surgery and during the index hospitalization. Deep sternal wound and mediastinitis were defined as a surgical site infection occurring within 3 months after surgery involving deep soft tissues, sternum, and/or mediastinum with purulent drainage or abscess, with or without fever (>38 C), detected at direct examination, during reoperation, or radiologic examination and requiring antibiotic treatment with or without reoperation. Post-operative atrial fibrillation was defined as any new event of atrial fibrillation occurred after CABG and detected at electrocardiogram, requiring or not pharmacological/electrical cardioversion. Acute kidney injury was defined as an increase in serum creatinine > _1.5 times the baseline level or serum creatinine increase > _26.5 lmol/L within 7 days after surgery and/or de novo renal replacement therapy. Patients with baseline estimated glomerular filtration rate (eGFR) <15 mL/min/ 1.73 m 2 or on chronic dialysis were excluded from the analysis on postoperative acute kidney injury. , and Fisher's Exact tests were used to compare baseline and operative covariates between the study cohorts. Predictive ability of bleeding risk scores were evaluated by the area under the receiver operating curves (ROC), and these were compared by the de Long's test. Since the study cohorts had a significantly different distribution of baseline and operative covariates, logistic regression models evaluating the primary outcomes were adjusted using the enter method for the following covariates: age, gender, baseline haemoglobin, baseline platelets count <150 Â 10 9 /L, eGFR, P2Y12 receptor inhibitors pause shorter than that suggested by the 2017 European Society for Cardiology (ESC) guidelines, aspirin administered within 7 days from surgery, oral anticoagulants administered within 2 days from surgery, diabetes, stroke, or transient ischaemic attack, atrial fibrillation, pulmonary disease, extracardiac arteriopathy, emergency procedure, left ventricular ejection fraction (LVEF) < _50%, critical preoperative state, prior cardiac surgery, prior percutaneous coronary intervention, off-pump surgery, bilateral internal mammary artery grafting, and number of distal anastomoses. Continuous variables were left untransformed. We did not include the duration of cross-clamping and cardiopulmonary bypass in to regression models because a significant number of patients in this series underwent off-pump CABG. The goodness of fit of regression models were tested with the Hosmer-Lemeshow's test. The anonymized centre codes were ranked in descending order of centre volume and was included in the regression models as a factor covariate. The risk-adjusted rate of adverse binary events was calculated by dividing, for each participating centre, the observed number of events by the expected number of events, and by multiplying this ratio by the average event rate of the entire series. The expected numbers of events were estimated using logistic regression. The estimated risk-adjusted rates of adverse events reported as odds ratios (OR) with 95% confidence intervals (CI) were summarized in caterpillar plots with the x-axis ordered for increasing adjusted rates. All tests were two-sided with the alpha level set at 0.05 for statistical significance.
Statistical analysis

Results
Baseline risk factors
Their baseline characteristics, operative data, preoperative antithrombotic regimen, and bleeding risk are summarized in Tables 1  and 2 .
Univariate analysis showed that participating centres differed in all baseline risk factors. In particular, the prevalence of recent myocardial infarction (MI) ranged from 17.9% to 62.5%, LVEF < _50% from 16.9% to 48.7%, and critical preoperative state from 1.5% to 21.8% ( Table 1) . Such imbalances in baseline risk factors translated in marked inter-institutional differences in the operative risk as shown by the mean EuroSCORE II, which ranged from 1.6 ± 1.3% to 5.2 ± 6.8% (P < 0.0001, Table 1 ). Similarly, also the surgical approach differed markedly between centres as the proportion of bilateral internal mammary artery grafting ranged from 0.9% to 88.5% and of off-pump surgery from 0.9% to 57.6% ( Table 1) .
Preoperative antithrombotic regimen
Aspirin was discontinued less than 7 days before CABG in 88.4% of patients (range between centres 67.3-98.6%, P < 0.0001) ( Table 2) . When adjusted for multiple covariates and participating centres, aspirin discontinued less than 7 days was not associated with an increased risk of resternotomy for bleeding (P = 0.898) as well as severe-massive bleeding defined as E-CABG bleeding grades 2-3 (P = 0.251) and UDPB bleeding grades 3-4 (P = 0.997).
Low molecular weight heparin, unfractionated heparin, and fondaparinux were administered preoperatively in 41.8% of patients (range between centres 4.4-97.4%, P < 0.0001) ( Table 2) . When adjusted for multiple covariates and participating centres, preoperative exposure to low molecular weight heparin, unfractionated heparin, and fondaparinux showed was not associated with an increased risk of resternotomy for bleeding (P = 0.264). However, these drugs increased significantly the risk of severe-massive bleeding defined as E-CABG bleeding grades 2-3 (P = 0.001, OR 1.51, 95% CI 1.17-1.95) and UDPB bleeding grades 3-4 (P = 0.016, OR 1.34, 95% CI 1.05-1.69).
Overall, 14.6% of patients were operated on with a pause of P2Y12 receptor antagonists of <5 days from surgery (range between centres 0.7-25.0%, P < 0.0001) (Figure 1) . Similarly, 11.6% of patients were operated on with a pause of P2Y12 receptor antagonists shorter than recently suggested by the 2017 ESC guidelines, i.e. ticagrelor <3 days, clopidogrel <5 days, and prasugrel <7 days before CABG (range between centres 0.7-24.8%, P < 0.0001) ( Figure 1) .
When adjusted for recent MI, LVEF < _50%, critical preoperative state, and emergency operation, the proportion of patients with pause of P2Y12 receptor antagonists <5 days from surgery (P < 0.0001) and pause of P2Y12 receptor antagonists shorter than recently suggested by the 2017 ESC guidelines (P < 0.0001) significantly differed between centres.
Logistic regression adjusted for multiple covariates and participating centres showed that patients operated on with a pause of P2Y12 receptor antagonists shorter than those recently suggested by the 2017 ESC guidelines had a significantly increased risk of E-CABG bleeding grades 2-3 (OR 1.66, 95% CI 1.27-2.17) and UDPB bleeding grades 3-4 (OR 1.50, 95% CI 1.16-1.93) but not of resternotomy for bleeding (adjusted OR 1.22, 95% CI 0.80-1.87). Similarly, logistic regression adjusted for multiple covariates and participating centres showed that patients operated on with a pause of P2Y12 receptor antagonists <5 days had a significantly increased risk of E-CABG bleeding grades 2-3 (OR 1.78, 95% CI 1.38-2.29) and UDPB bleeding grades 3-4 (OR 1.43, 95% CI 1.12-1.83), whilst a trend towards increased risk of resternotomy for bleeding was observed as well (adjusted OR 1.36, 95% CI 0.92-2.01).
Estimated bleeding risk
The bleeding risk estimated by the WILL-BLEED, CRUSADE, Papworth, TRUST, TRACK, and CathPCI risk scores were significantly different between centres (all scores, P < 0.0001, Table 2 ). Among these bleeding risk scoring methods, the WILL-BLEED and the CathPCI bleeding scores had the largest area under the curve to predict resternotomy for bleeding, E-CABG bleeding grades 2-3 and UDPB bleeding grades 3-4 ( Table 3) . Similar results were observed among patients with and without preoperative pause of P2Y12 receptor antagonists according to the 2017 ESC guidelines ( Table 3) . The WILL-BLEED score had a significantly larger area under the curve to predict E-CABG bleeding grades 2-3 (P = 0.024) than the CathPCI bleeding score but not for resternotomy for bleeding (P = 0.456) and UDPB bleeding grades 3-4 (P = 0.483). The mean WILL-BLEED score ranged from 2.3 ± 3.0 to 5.6 ± 4.6 and the mean CathPCI score ranged from 36 ± 17 to 52 ± 20 between participating centres ( Table 2) . Baseline risk factors Age (years) 67.4 ± 9.4 67.8 ± 9.6 67.6 ± 9.2 66.6 ± 9.0 66.1 ± 8.9 69.3 ± 9.8 67.9 ± 9.5 64.8 ± 9.0 68.1 ± 9.6 68.3 ± 8.5 66.1 ± 9.1 68.1 ± 9.7 66.1 ± 9.0 67.4 ± 9.3 67.9 ± 10.2 68.3 ± 8.7 <0.0001
Female 1160 (16) 153 (15) 126 (17) 79 (12) 93 (15) 102 (20) 88 (18) 90 (18) 80 (18) 90 (21) 67 (16) 55 (14) 42 (19) 37 (17) 32 (16) 26 (16) (8) 54 (5) 83 (11) 52 (8) 39 (7) 26 (85) 51 (10) 50 (10) 42 (10) 39 (9) 32 (8) 62 (15) 15 (7) 10 (5) 20 (10) 13 (8) <0.0001
Dialysis 78 (1) 14 (1) 3 (0) 3 (0) 4 (1) 4 (1) 6 (1) 7 (1) 17 (4) 4 (1) 4 (1) 3 81) 1 (0) 4 (2) 4 (2) (6) 93 (9) 32 (4) 30 (5) 48 (8) 16 (3) 35 (7) 25 (5) 11 (3) 41 (10) 27 (7) 9 (2) 16 (2) 16 (7) 11 (5) 20 (12) <0.0001
Atrial fibrillation 566 (8) 116 (11) 54 (7) 31 (5) 43 (7) 57 (11) 50 (10) 23 (5) 33 (7) 47 (11) 25 (6) 29 (7) 16 (7) 11 (5) 16 (8) 15 (9) <0.0001
Pulmonary disease 738 (10) 138 (13) 58 (8) 41 (6) 41 (7) 39 (8) 26 (5) 120 (24) 11 (3) 54 (13) 25 (6) 28 (7) 30 (13) (29) 101 (23) 44 (10) 101 (25) 84 (21) 73 (32) (35) 112 (26) 202 (49) 86 (21) 68 (30) 38 (17) 82 (40) 42 (25) <0.0001
Prior PCI 1490 (21) 253 (24) 126 (17) 161 (24) 115 (19) 130 (25) 89 (18) 109 (22) 70 (16) 91 (21) 91 (22) 44 (11) 72 (32) 52 (23) 43 (21) 44 (26) <0.0001
Prior cardiac surgery 39 (1)
Critical preoperative state 450 (6) 35 (3) 52 (7) 18 (3) 9 (2) 14 (3) 70 (13) 12 (2) 12 (3) 44 (10) 36 (9) 88 (22) 14 (6) 7 (3) 26 (13) 13 (8) <0.0001
Emergency procedure 334 (5) 106 (10) 24 (3) 9 (1) 5 (1) 59 (11) 19 (4) 19 (4) 11 (3) 43 (10) 2 (1) 11 (3) 12 (5) 1 (0) 10 (5) 3 (2) <0.0001
EuroSCORE II (%) 2.8 ± 4.1 2.8 ± 4.3 2.1 ± 3.0 1.6 ± 1.3 1.9 ± 2.4 3.0 ± 4.6 3.4 ± 3.8 2.3 ± 3.0 3.1 ± 4.1 4.1 ± 6.3 2.6 ± 3.2 4.1 ± 5.8 3.7 ± 5.1 2.5 ± 3.5 5.2 ± 6.8
2.8 ± 4.7 <0.0001
Operative data Off-pump surgery 1470 (21) 517 (50) 5 (1) 84 (13) 6 (1) 171 (33) 10 (2) 92 (19) 4 (1) 241 (56) 239 (58) 14 (4) 34 (15) 23 (10) 9 (4) 21 (13) <0.0001
No. of distal anastomoses 2.7 ± 0.9 2.3 ± 0.8 2.7 ± 0.7 2.4 ± 0.8 3.0 ± 0.8 3.1 ± 1.0 2.4 ± 0.7 2.3 ± 0.8 2.8 ± 0.8 3.6 ± 1.0 2.4 ± 0.8 3.5 ± 1.0 2.4 ± 1.0 2.6 ± 0.8 2.7 ± 0.9 2.9 ± 1.0 <0.0001 BIMA grafting 2578 (36) 582 (56) 78 (10) 466 (71) 243 (40) 463 (89) 5 (1) 5 (1) 47 (11) 17 (4) 245 (59) 273 (68) 35 (16) 49 (22) 50 (24) 20 (12) (7) 78 (18) 75 (18) 90 (9) 3 (0) 4 (1) 23 (4) 27 (5) 7 (1) 6 (1) 3 (1) 27 (6) 6 (1) 0 2 (1) 2 (1) 9 (4) (16) 12 (2) 25 (4) 34 (6) 71 (14) 62 (12) 28 (6) 12 (3) 65 (15) 62 (15) 3 (1) 4 (2) 7 (3) 13 ( 7 (1) 3 (1) 1 (0) 19 (5) 0 2 (1) 2 (1) 11 (5) 1 (1) <0.0001
Prasugrel pause < 7 days 46 (1) 2 (0) 4 (1) 2 (0)
3 (1) 2 (1) 1 (0) 13 ( (7) 113 (26) 92 (22) 3 (1) 11 (5) 20 (9) 45 (22) (25) 19 (3) 31 (5) 56 (9) 98 (19) 71 (14) 37 (8) 17 (4) 93 (22) 81 (20) 3 (1) 9 (4) 10 (5) 33 (16) 12 (7) <0.0001
Oral anticoagulants 47 (5) 8 (1) 25 (4) 25 (4) 3 (1) 18 (4) 5 (1) 12 (3) 39 (9) 6 (1) 13 (3) 3 (1) 7 (3) 4 (2) 8 (5) <0.0001
Warfarin/coumadin 162 (2) 28 (3) 5 (1) 14 (2) 14 (2) 3 (1) 17 (3) 4 (1) 11 (3) 33 (8) 2 (1) 12 (3) 3 (1) 6 (3) 3 (2) 7 (4) <0.0001
Rivaroxaban 32 (0)
14 (1) 1 (0) 7 (1) 3 ( Bleeding risk scores WILL-BLEED score 4.0 ± 3.6 3.7 ± 3.2 2.7 ± 3.2 2.3 ± 3.0 3.7 ± 3.2 3.4 ± 3.6 5.2 ± 3.8 5.5 ± 3.2 4.3 ± 3.5 5.6 ± 4.6 4.2 ± 3.7 4.2 ± 3.7 4.2 ± 3.7 4.6 ± 3.0 5.9 ± 3.6 3.0 ± 3.7 <0.0001 CRUSADE score 26 ± 14 25 ± 13 24 ± 13 23 ± 11 23 ± 12 28 ± 14 28 ± 14 25 ± 14 30 ± 15 26 ± 15 29 ± 14 24 ± 13 28 ± 14 27 ± 14 30 ± 14 27 ± 14 <0.0001
Continued
Resternotomy for bleeding
Overall, 186 patients (2.6%) underwent resternotomy for excessive bleeding with significant variation between centres (P < 0.0001, Table 4 ). One hundred and forty-five patients (75.7%) underwent resternotomy for bleeding within 12 h from surgery and their mean chest drainage output was 845 ± 376 mL (median 800 mL, IQR 400, range 200-2000 mL). Among these patients, the amount of blood loss until reoperation significantly differed between centres (range mean 607 ± 257 mL to 1073 ± 505 mL, P < 0.0001). A significant difference between centres was observed also in terms of incidence of late resternotomies (later than 12 h after surgery: range 0-87.5%, P < 0.0001, Table 4 ). Surgical site bleeding was identified in 89 patients (48.6%), diffuse bleeding in 74 patients (40.4%), whilst both diffuse and surgical site bleeding was identified in 20 patients (10.8%). No specific data on the site of bleeding were reported in three patients. Surgical site bleeding was detected in 59.6% of these patients with significant variation between centres (range 0% to 84.6%, adjusted P = 0.003, Table 4 , Figure 2 ). Details on the sources of bleeding are reported in Table 5 . Two or more sources of surgical bleeding were observed in 12 patients. Patients with diffuse bleeding had a higher risk of hospital/ 30-day mortality compared to patients with any surgical site bleeding (13.5% vs. 9.1%, adjusted OR 3.195, 95% CI 0.870-11.730), but the difference did not reach statistical significance.
Red blood cell transfusion
The rate of RBC transfusion in the overall series was 40.9% and ranged from 24.1% to 71.3% between centres (P < 0.0001, Table 4 ). Caterpillar plot showed that three centres (F, K, I) had a significantly higher adjusted rates and four centres (B, C, D, M) had significantly lower adjusted rates of RBC transfusion.
Severe-massive perioperative bleeding
The rate of UDPB bleeding grades 3-4 in the overall series was 8.4% and ranged from 3.7% to 22.3% between centres (P < 0.0001, Table  4 ). The rate of E-CABG bleeding grades 2-3 in the overall series was 6.5% and ranged from 0.4% to 16.4% between centres (P < 0.0001, Table 4 ). Caterpillar plot showed that a number of centres had a significantly lower and higher risk of severe-massive bleeding, respectively ( Figure 3) . However, centres performed differently in terms of UDPB and E-CABG severe-massive bleeding. When UDPB bleeding grades 3-4 were chosen as an endpoint for its more comprehensive bleeding-and blood products-related parameters, three centres (C, K, I) had significantly higher risk-adjusted rates of severe-massive bleeding, while six centres (B, E, H, J, M, N) had a significantly lower risk-adjusted rates of severe-massive bleeding (Figure 3) . Three centres (C, F, I) had significantly higher and three centres (G, K, M) significantly lower risk-adjusted rates of E-CABG bleeding grades 2-3 ( Figure 3 ).
Clinical implications of severe perioperative bleeding
When adjusted by multiple covariates, resternotomy for bleeding (adjusted OR 5.042, 95% CI 2.85-8.92), UDPB bleeding grades 3-4 (adjusted OR 6.61, 95% CI 4.42-9.88), and E-CABG bleeding grades .. ......................................................................................................................................................................................................................................................... .. ...................................................................................................................................................................................................................................................................   ................................................................................................................................................................................................................................................................................................................ ..... 
Discussion
This study showed that: (i) the risk of post-operative bleeding as assessed by several risk scores significantly varied between centres; (ii) adherence to the currently recommended discontinuation period for P2Y12 receptor antagonists varied significantly between centres, and this had a significant impact on the occurrence of post-operative major bleeding; (iii) the rate of Figure 3 Risk-adjusted rates with 95% confidence intervals of red blood cell (RBC) transfusion as well as severe-massive bleeding according to the Universal Definition of Perioperative Bleeding (UDPB) and E-CABG bleeding severity criteria in the participating centres. Red lines are the rates in the overall series, red dots indicate centres with significantly higher, and blue dots indicate centres with significantly lower risk-adjusted rates.
Variation in preoperative antithrombotic strategy and bleeding confirm that such inter-institutional differences persisted during the last three decades most likely because of a lack of common, effective patient-blood management strategy. The uncertainty about the safety of a liberal threshold for haemoglobin level in RBC transfusion is one of the key factors underlying these differences. A recent study by Murphy et al. 15 failed to demonstrate the superiority of a restrictive over a liberal policy of blood transfusion in patients undergoing adult cardiac surgery. This means that strategies aiming to improve the outcomes by preventing perioperative blood loss may be more efficacious than targeting only a reduction of the exposure to allogenic blood. Indeed, the present findings demonstrate a large heterogeneity in the estimated risk of bleeding, prevalence of early discontinuation of potent antiplatelets and rates of severe-massive bleeding, which had a significant impact on the outcome of patients undergoing isolated CABG. In this regard, our decision to investigate severe bleeding rather than the exposure to any amount of RBC transfusion as in previous studies [2] [3] [4] [5] was substantiated by the evidence of a formidable risk of early mortality in patients undergoing reoperation for bleeding 16 and/or transfusion of >4 units of RBCs. 7, 17 This study showed that the measures to counteract increased bleeding risk, of early discontinuation of potent antiplatelets and to reduce of the risk of surgical bleeding should be implemented in centres with high rates of severe bleeding. The combined evidence of an individual surgeon's impact on perioperative blood loss 18 and a high rate of surgical sources of bleeding detected at reoperation 19 suggests that meticulous surgical technique could be an important issue in preventing significant bleeding. In fact, the individual patient's risk of bleeding and recent exposure to potent antiplatelets were not associated with an increased risk of reoperation for bleeding. This finding further confirm that excessive bleeding requiring reoperation is most often due to factors related to surgical technique rather than perioperative coagulopathy. Furthermore, these findings may explain why the discrimination ability of current bleeding risk scores in predicting severe-massive bleeding is limited ( Table 3) . One of the main findings of this analysis is the significant heterogeneity of preoperative exposure to P2Y12 receptor antagonists, which ranged from 7% to 63% in the participating centres ( Table 2) . Even more striking is the inter-institutional difference in the incidence of preoperative discontinuation of P2Y12 receptor antagonists <5 days from surgery or with a pause a suggested by the 2017 ESC guidelines, i.e. ticagrelor <3 days, clopidogrel <5 days and prasugrel <7 days before CABG (range between centres 0.7-24.8%, P < 0.0001) (Figure 1) . The attention to the currently recommended washout period for P2Y12 receptor antagonists to minimize post-operative bleeding markedly varied between institutions and, when these guidelines were not followed, this resulted in an increased risk of severemassive defined according to the E-CABG and UDPB criteria. When UDPB bleeding grades 3-4 were chosen as an endpoint for its more comprehensive parameters, i.e. chest drainage output, resternotomy for bleeding, transfusion of >4 units of RBC, and/fresh frozen plasm and use of procoagulants, three centres had significantly higher and six centres significantly lower rates of severe-massive bleeding compared to the results of overall series also when adjusted for multiple baseline risk factors (Figure 3) . These findings confirm that a few centres adopted effective strategies to prevent significant blood loss after CABG, and this effect was evident when adjusted for potential confounders.
A few limitations may affect the results of this study. First, we do not have preoperative data on platelet reactivity, fibrinogen level, thrombin generation, and other coagulation parameters for a detailed inter-institutional analysis of baseline coagulopathies in these patients. Second, the lack of specific data on point-of-care testing of post-operative coagulopathy prevents a more in depth analysis of the causes of excessive post-operative bleeding. Third, we do not have data on individual surgeons, which prevents conclusive results on the impact of individual surgical skills on post-operative bleeding end-points. Fourth, stratification of the severity of perioperative bleeding in cardiac surgery has been based mainly on the evaluation of RBC transfusion, but this fails to identify those patients with significant bleeding and high risk of other adverse events. The UDPB and E-CABG bleeding classifications are more detailed and specific tools for stratification of the severity of perioperative bleeding and its prognostic implications, 20 but they differ significantly in their characteristics. Therefore, participating centres to this study behaved somewhat differently in terms of rates of severe-massive bleeding as defined by the UDPB and E-CABG bleeding classifications. Such heterogeneity makes these findings generalizable.
Conclusions
This study documented a significant inter-institutional heterogeneity in the estimated risk of bleeding, preoperative antithrombotic policy, and discontinuation of antiplatelet drugs, incidence of severe-massive bleeding as well as in the use of blood products. The present findings suggest that inter-institutional variation of perioperative bleeding and use of blood products should be considered for a correct interpretation of the results of multicentre studies. Adherence to the current guidelines on the early discontinuation of P2Y12 receptor antagonists and meticulous surgical technique aimed to reduce surgical site bleeding seems to be of utmost importance to prevent excessive bleeding, exposure to blood products and improve the outcome after CABG.
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